MRI methods are widely used to follow the pathological evolution of multiple sclerosis in life
and its modification by treatment. To date, measures of the number and volume of …

Brain atrophy has emerged as a clinically relevant component of disease progression in
multiple sclerosis. Progressive loss of brain tissue bulk can be detected in vivo in a sensitive …

Brain atrophy measured by MRI is a potentially useful tool for monitoring disease
progression in multiple sclerosis. The location, extent and mechanisms of brain atrophy in …

Background: IV methylprednisolone (IVMP) has been used to treat relapses in patients with
relapsing-remitting (RR) MS, but its effect on disease progression is not known. Furthermore …

In patients who present with clinically isolated syndromes suggestive of multiple sclerosis,
interferon beta-1a is effective in delaying evolution to clinically definite disease and in …

Background In multiple sclerosis (MS), brain atrophy depicted by magnetic resonance
imaging reflects overall tissue loss, including axonal loss. Objective To determine the course …

We have recently reported brain atrophy in the early stages of primary progressive multiple
sclerosis (PPMS), affecting both grey and white matter (GM and WM). However, to date no …

Background: Investigation of atrophy data from a pivotal natalizumab trial has demonstrated
an increased rate of volume loss, compared to placebo, after the first year of therapy. It was …

Objective: The objectives of the present study were to assess brain atrophy in multiple
sclerosis (MS) patients during different disease stages and to investigate by PET and [11C] …

Evaluation of brain and spinal cord atrophy by magnetic resonance imaging (MRI) has
become an increasingly important component of understanding the multiple sclerosis (MS) …